LANGUAGE
Press Releases
Search
-
26 Sep 2022
New survey shows low adherence to guidelines in sepsis care puts patients at risk
Marcy l’Étoile, France and London, UK – To mark Sepsis Awareness Month, bioMérieux, a world leader in in vitro diagnostics with a long-standing commitment to the fight against sepsis, and the UK Sepsi...
-
31 Aug 2022
First-Half 2022 Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2022.
-
22 Aug 2022
The SPECIFIC REVEAL® Rapid AST System has received Breakthrough Device Designation from the U.S. Food and Drug Administration
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that the U.S. Food and Drug Administration (FDA) has granted its Breakthrough Device Designation for the SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility Test (AST) System.
-
28 Jul 2022
bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®
bioMérieux announced the FDA Clearance of VIDAS® NEPHROCHECK® assay to detect kidney stress in patients at risk of acute kidney injury (AKI).
-
07 Jul 2022
bioMérieux launches 3P® ENTERPRISE, an innovative solution for the pharma industry
bioMérieux, a world leader in the field of in vitro diagnostics, launches 3P® ENTERPRISE, an innovative solution designed to ensure environmental monitoring processes are fully efficient and under control at all times.
-
06 Jul 2022
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec SE and bioMérieux announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).
-
19 May 2022
Closing of the acquisition of Specific Diagnostics
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has finalized the acquisition of Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.
-
13 May 2022
bioMérieux announces the CE marking of VIDAS® tests for Chikungunya virus diagnosis
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its automated tests to diagnose Chikungunya virus (CHIKV) infection on immunoassay instruments of the VIDAS® range.
-
04 May 2022
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® Joint Infection (JI) Panel has received De Novo authorization from the US Food and Drug Administration (FDA). This panel tests for 31 pathogens implicated in most acute joint infections, and also includes 8 antimicrobial resistance (AMR) genes.
-
12 Apr 2022
Specific Diagnostics acquisition
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.
-
11 Apr 2022
First-Quarter 2022 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2022.
-
18 Mar 2022
bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system
bioMérieux, a world leader in the field of in vitro diagnostics, announces that VITEK® MS PRIME, its new MALDI-TOF mass spectrometry identification system, has received 510(k) clearance from the U.S. ...
-
02 Mar 2022
bioMérieux – 2021 Financial Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on March 1 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial st...
-
17 Feb 2022
MYACUTECASE™, a free mobile application by bioMérieux to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics
bioMérieux, a world leader in the field of in vitro diagnostics, launches MYACUTECASETM. This mobile application, the first of a kind developed by bioMérieux, is an aid in the interpretation of VIDAS®...
-
06 Jan 2022
French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance
The ARPEGE project aims to develop a set of solutions to strengthen the ability of healthcare institutions to fight antibiotic resistance. The consortium, led by Antabio, has been awarded close to €9 ...